# EDGAR Filing Document

**Accession Number:** 0000882095
**File Stem:** 0001308179-26-000107
**Filing Date:** 2026-3
**Character Count:** 8898
**Document Hash:** a80392647397b764cd119d1c3f7bf38b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001308179-26-000107.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0001308179-26-000107

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 12

**FILED AS OF DATE**: 20260320

**DATE AS OF CHANGE**: 20260320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19731
- **FILM NUMBER:** 26778157

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**SCHEDULE 14A**

**PROXY STATEMENT PURSUANT TO SECTION 14(a)**<br>**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**(Amendment No.)**

---

| | | | |
|:---|:---|:---|:---|
| ![](check01.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;Filed by the Registrant | ![](uncheck.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;Filed by a Party other than the Registrant |

---

---

| | |
|:---|:---|
| **Check the appropriate box:** | **Check the appropriate box:** |
| ![](uncheck.jpg) | Preliminary Proxy Statement |
| ![](uncheck.jpg) | **Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))** |
| ![](uncheck.jpg) | Definitive Proxy Statement |
| ![](check01.jpg) | Definitive Additional Materials |
| ![](uncheck.jpg) | Soliciting Material under §240.14a-12 |

---

**GILEAD SCIENCES, INC.**

![](logo.jpg)

*(Name of Registrant as Specified in Its Charter)*

*(Name of Person(s) Filing Proxy Statement, if other than the Registrant)*

---

| | |
|:---|:---|
| **Payment of Filing Fee (Check all boxes that apply):** | **Payment of Filing Fee (Check all boxes that apply):** |
| ![](check01.jpg) | **No fee required.** |
| ![](uncheck.jpg) | **Fee paid previously with preliminary materials.** |
| ![](uncheck.jpg) | **Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;![](logo1.jpg)GILEAD SCIENCES, INC.<br> ATTN: INVESTOR RELATIONS<br> 333 LAKESIDE DRIVE<br> FOSTER CITY, CA 94404 | Your **Vote** Counts!<br> **GILEAD SCIENCES, INC.**<br> 2026 Annual Meeting<br> Vote by April 29, 2026<br> 8:59 PM PDT<br> ![](lgild2026_defa14ax1x2.jpg) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;![](logo1.jpg)GILEAD SCIENCES, INC.<br> ATTN: INVESTOR RELATIONS<br> 333 LAKESIDE DRIVE<br> FOSTER CITY, CA 94404 | Your **Vote** Counts!<br> **GILEAD SCIENCES, INC.**<br> 2026 Annual Meeting<br> Vote by April 29, 2026<br> 8:59 PM PDT<br> ![](lgild2026_defa14ax1x2.jpg) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;![](logo1.jpg)GILEAD SCIENCES, INC.<br> ATTN: INVESTOR RELATIONS<br> 333 LAKESIDE DRIVE<br> FOSTER CITY, CA 94404 | Your **Vote** Counts!<br> **GILEAD SCIENCES, INC.**<br> 2026 Annual Meeting<br> Vote by April 29, 2026<br> 8:59 PM PDT<br> ![](lgild2026_defa14ax1x2.jpg) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;V87556-P47038 |  |

---

You invested in GILEAD SCIENCES, INC. and it's time to vote!<br>**This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on April 30, 2026, 10:00 a.m. Pacific Daylight Time, virtually at www.virtualshareholdermeeting.com/GILD2026.**

Get informed before you vote<br>You can view the Notice and Proxy Statement and Form 10-K online by visiting www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by making a request prior to April 16, 2026. To submit a request for a paper or email copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

---

| | | |
|:---|:---|:---|
| ![](lgild2026_defa14ax1x3.jpg) | For complete information and to vote, visit **www.ProxyVote.com** | For complete information and to vote, visit **www.ProxyVote.com** |
| ![](lgild2026_defa14ax1x3.jpg) | Control # | ![](lgild2026_defa14ax1x6.jpg) |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Smartphone users**<br> Point your camera here and<br> vote without entering a<br> control number | ![](lgild2026_defa14ax1x5.jpg) | &nbsp;&nbsp;&nbsp;&nbsp; **Vote Virtually at the Meeting\***<br> April 30, 2026<br> 10:00 a.m. Pacific Daylight Time |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Smartphone users**<br> Point your camera here and<br> vote without entering a<br> control number | Virtually at:<br> www.virtualshareholdermeeting.com/GILD2026 | Virtually at:<br> www.virtualshareholdermeeting.com/GILD2026 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](lgild2026_defa14ax1x4.jpg) | Virtually at:<br> www.virtualshareholdermeeting.com/GILD2026 | Virtually at:<br> www.virtualshareholdermeeting.com/GILD2026 |
|  | Virtually at:<br> www.virtualshareholdermeeting.com/GILD2026 | Virtually at:<br> www.virtualshareholdermeeting.com/GILD2026 |

---

\*Please check the meeting materials for any special requirements for meeting attendance.<br>

**Vote at www.ProxyVote.com**

**THIS IS NOT A VOTABLE BALLOT**

This is an overview of the proposals being presented at the upcoming Annual Meeting. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to obtain the proxy materials and to vote on these important matters.

---

| | | | |
|:---|:---|:---|:---|
| **Voting Items** | **Voting Items** | **Board<br> Recommends** | **Board<br> Recommends** |
| 1. | To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. |  |  |
|  | **Nominees:** |  |  |
| 1a. | Jacqueline K. Barton, Ph.D. | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 1b. | Jeffrey A. Bluestone, Ph.D. | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 1c. | Sandra J. Horning, M.D. | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 1d. | Kelly A. Kramer | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 1e. | Ted W. Love, M.D. | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 1f. | Harish Manwani | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 1g. | Daniel P. O'Day | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 1h. | Javier J. Rodriguez | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 1i. | Anthony Welters | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 2. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 3. | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 4. | To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. | ![](lgild2026_defa14ax2x1.jpg) | **For** |
| 5. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. | ![](lgild2026_defa14ax2x2.jpg) | **Against** |
| 6. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. | ![](lgild2026_defa14ax2x2.jpg) | **Against** |
| 7. | To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting. | ![](lgild2026_defa14ax2x2.jpg) | **Against** |

---

&nbsp;&nbsp;Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

V87557-P47038